Last reviewed · How we verify
NRT (NicoDerm CQ)
NRT (NicoDerm CQ) is a Nicotine replacement therapy (NRT) Small molecule drug developed by University of California, San Francisco. It is currently FDA-approved for Smoking cessation as an aid to quit smoking. Also known as: nicotine patch.
NicoDerm CQ delivers nicotine transdermally to replace nicotine from cigarettes and reduce withdrawal symptoms during smoking cessation.
NRT (NicoDerm CQ) is a small molecule used to treat conditions such as smoking cessation, nicotine dependence, and coronary heart disease. It is typically used as a second-line intervention for adult smokers who do not quit with NRT, and is available in various forms including patches, gum, and lozenges.
At a glance
| Generic name | NRT (NicoDerm CQ) |
|---|---|
| Also known as | nicotine patch |
| Sponsor | University of California, San Francisco |
| Drug class | Nicotine replacement therapy (NRT) |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Smoking Cessation / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
Nicotine is absorbed through the skin via a transdermal patch, providing steady-state nicotine levels that satisfy the body's dependence on the drug without the harmful combustion byproducts of smoking. This reduces cravings and withdrawal symptoms such as irritability, anxiety, and difficulty concentrating, allowing smokers to gradually reduce their nicotine dependence over time.
Approved indications
- Smoking cessation as an aid to quit smoking
Common side effects
- Skin irritation at patch application site
- Headache
- Nausea
- Dizziness
- Sleep disturbances
- Vivid dreams
Key clinical trials
- iCanQuit Smoking Cessation Among Hispanic Adults (PHASE3)
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- Rural Smoking Cessation (NA)
- My Path to Quit Tobacco (PHASE4)
- Varenicline and Combined NRT for Smoking Cessation (PHASE4)
- Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation (NA)
- Feasibility of Delivering VergeRx at FQHCs (NA)
- Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NRT (NicoDerm CQ) CI brief — competitive landscape report
- NRT (NicoDerm CQ) updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI
Frequently asked questions about NRT (NicoDerm CQ)
What is NRT (NicoDerm CQ)?
How does NRT (NicoDerm CQ) work?
What is NRT (NicoDerm CQ) used for?
Who makes NRT (NicoDerm CQ)?
Is NRT (NicoDerm CQ) also known as anything else?
What drug class is NRT (NicoDerm CQ) in?
What development phase is NRT (NicoDerm CQ) in?
What are the side effects of NRT (NicoDerm CQ)?
What does NRT (NicoDerm CQ) target?
Related
- Drug class: All Nicotine replacement therapy (NRT) drugs
- Target: All drugs targeting Nicotinic acetylcholine receptors
- Manufacturer: University of California, San Francisco — full pipeline
- Therapeutic area: All drugs in Smoking Cessation / Addiction Medicine
- Indication: Drugs for Smoking cessation as an aid to quit smoking
- Also known as: nicotine patch
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing